SCHEMBL5617887

SCHEMBL5617887

CNc1nccn2c(-c3ccc(NC(=O)NCc4ccc(OCCN5CCOCC5)cc4)cc3)cnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 4/20 0.52
▸ FLT3 P36888 4/20 0.52
▸ AURKA O14965 3/20 0.51
▸ TTK P33981 1/20 0.47
▸ SRC P12931 2/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ LYN P07948 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5618519 0.93 AURKA (0.48) KDRFLT3AURKATTKSRC
SCHEMBL5619180 0.87 MAPKAPK5 (0.57) FLT3TTKNAMPTMTOR
SCHEMBL5394701 0.86 SRC (0.53) KDRFLT3SRC
SCHEMBL5394670 0.86 TTK (0.54) FLT3TTKEPHX2NAMPT
SCHEMBL4655966 0.84 SMN1; SMN2 (0.56) KDRFLT3TTK
SCHEMBL5619165 0.84 TTK (0.55) TTKHDAC1NAMPT
SCHEMBL5618704 0.83 TTK (0.48) FLT3AURKATTKAURKBEPHX2
SCHEMBL5618589 0.81 TTK (0.58) FLT3TTKNAMPTMTOR
SCHEMBL5619038 0.81 TTK (0.57) TTKNAMPT
SCHEMBL5618446 0.81 TTK (0.57) TTKEPHX2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 KDR 622/4885FLT3 216/4885AURKA 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback